How CMA reforms could impact pet insurance pricing – Pearson Ham

The Competition and Markets Authority’s (CMAs) intervention in the UK veterinary sector represents a significant structural development in pet healthcare pricing.

Among other measures, written prescriptions are to be capped at £21, and practices will have to publish price lists for services. While the reforms are intended to improve transparency and consumer choice, their implications for the pet insurance market are likely to be both material and complex.

At a fundamental level, the introduction of capped prescription fees and mandatory price disclosure should place downward pressure on certain routine and ongoing treatment costs. For insurers, this may result in a modest reduction in claims severity, particularly in cases involving chronic conditions that require long-term medication. The CMA’s finding that pet owners could save more than £200 annually by purchasing medicines online highlights a long-standing inefficiency within the system. As policyholders increasingly obtain written prescriptions and source medication externally, insurers may see lower reimbursement costs for pharmaceutical claims.

However, expectations of widespread premium reductions should be approached with caution. The reforms are more likely to redistribute costs rather than significantly reduce the overall expense of veterinary care. Greater transparency, especially for procedures exceeding £500, may bring increased visibility to the true cost of advanced treatments, which have risen due to technological progress and higher clinical standards. As awareness of these costs grows, demand for comprehensive insurance cover may increase, placing upward pressure on premiums.

The requirement for veterinary practices to publish detailed price lists and disclose ownership structures may also increase competitive dynamics within the sector. In principle, this could help moderate price inflation over time. However, the UK veterinary market remains relatively concentrated, with a substantial proportion of practices owned by larger corporate groups. Transparency alone may not be sufficient to drive meaningful price competition in the near term, particularly in regions where consumer choice is limited. As a result, insurers are likely to continue pricing policies against a backdrop of elevated treatment costs.

Behavioural changes among pet owners will also be an important factor. Improved access to pricing information and comparison tools is expected to encourage more cost-conscious decision making. This may lead to changes in claims patterns, with some owners opting to limit high-cost interventions in the absence of insurance. By contrast, insured individuals, who are less exposed to the full financial burden, may continue to pursue advanced treatments. This divergence could reinforce the perceived value of pet insurance and sustain demand, even in an environment of rising premiums.

From an operational perspective, insurers may benefit from the increased availability of pricing data. Standardised and accessible information could support more precise underwriting and enable insurers to refine their risk models based on geographic and provider-specific cost variations. Over time, this may lead to more differentiated pricing approaches, rather than broad adjustments across entire portfolios.

The CMA’s reforms represent a constructive step towards greater transparency and improved consumer outcomes. However, their effect on pet insurance pricing is likely to be nuanced. While some cost efficiencies may emerge, they are expected to be offset by continued advances in veterinary care and sustained demand for high-quality treatment. For insurers, the outcome is unlikely to be a reduction in premiums, but rather a transition towards more sophisticated and data-driven pricing strategies within a more transparent marketplace. Understanding how competitor pricing is evolving and how this impacts your competitive position will be more important than ever.